{
    "Trade/Device Name(s)": [
        "SoloV2\u2122M Blood Glucose Monitoring System",
        "SoloV2\u2122 Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Biotest Medical Corporation",
    "510(k) Number": "K093764",
    "Predicate Device Reference 510(k) Number(s)": [
        "K091815"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "CGA"
    ],
    "Summary Letter Date": "March 2, 2010",
    "Summary Letter Received Date": "February 1, 2010",
    "Submission Date": "January 26, 2010",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "SoloV2\u2122M Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Glucose oxidase method"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Analyzer",
        "System",
        "Lancing device",
        "Test strip",
        "Control solution"
    ],
    "Document Summary": "FDA 510(k) summary for SoloV2\u2122M Blood Glucose Monitoring System for quantitative glucose measurement using capillary whole blood from finger and forearm",
    "Indications for Use Summary": "Quantitative measurement of glucose in fresh capillary whole blood from finger and forearm, for monitoring diabetes control by healthcare professionals and people with diabetes at home; not for diagnosis, screening, or use with neonates; includes speaking function for users with low vision",
    "fda_folder": "Clinical Chemistry"
}